Ana Montalban-Arques’ novel therapeutic approach applies bacteria as a stand-alone therapy for colon cancer, a therapeutic approach that shows striking efficacy of bacteria as monotherapy.
Dr. Ana Montalban-Arques joined the University of Zurich in 2018. Since then she has been leading a project about gut microbiota and its influence on colorectal cancer development. In 2019, she received the CCCZ fellowship, which helped to develop her translational project. In 2020, she was awarded with the UZH Entrepreneur Fellowship and with the SNF/InnoSuisse BRIDGE PoC. This funding allows her to turn this translational research project into a spin-off company, with the aim of developing a live biotherapeutic product as an oral therapy for the treatment of colorectal cancer.